 |
|
|
| |
Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization - low treatment rates & high resource utilization rate too with IFN-based therapies boceprevir or telaprevir or INF-based Double Therapy In A Large Health Maintenance Organization
|
| |
| |
in light of the trend to prioritize treatment for advanced disease this study highlights the resources being devoted to treatment with previous therapies: Peg/Rbv, telaprevir+PR, BOC+PR and the authors conclude:
In conclusion, health care resource utilization was significantly increased
with triple vs dual therapy. Future treatment may require less health care
resources due to increased potency, expected shorter treatment duration
and better side effect profiles.
and the dollar costs associated:
and this study demonstrates the leaps the new interferon-free therapies bring, and the the limitations of previous Peg/Rbv therapy with telaprevir or boceprevir or before with PR alone-
Only approximately 8-12% of patients with chronic HCV infection received anti-HCV treatment both in the pre-PI as well as in post-PI era.
Low treatment rates and suboptimal treatment completion rates to HCV therapy: A real world analysis of a large US cohort - (05/05/14)
Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization
http://www.natap.org/2014/DDW/DDW_04.htm
Reported by Jules Levin
EASL 2014 London, UK
Lisa M. Nyberg1, Kevin M. Chiang2, Yi-Lin Wu2, Anders H. Nyberg1, Zobair M. Younossi3, T. Craig Cheetham2
1Hepatology Research, Kaiser Permanente, San Diego, CA, United States; 2Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, United States; 3Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, United States.
|
| |
|
|
|
|
|
